Please assess the completion status of the following clinical trial:

Trial Title: Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Healthy adults between the ages of 18-70 years inclusive~2. Based on history and examination, in good general health and without history of any of the conditions listed in the exclusion criteria~3. Received at least one licensed influenza vaccine from 2014 to the present~4. Able and willing to complete the informed consent process~5. If enrolled in Group 1: Available for clinic visits for 52 weeks after enrollment and through an influenza season~6. If enrolled in Group 2A, 2B, 2C, or 2D: Available for clinic visits for 68 weeks after enrollment and through an influenza season~7. Willing to have blood samples collected, stored indefinitely, and used for research purposes~8. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~9. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 28 days before enrollment~   Laboratory Criteria within 28 days before enrollment~10. White blood cells (WBC) and differential either within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval~11. Total lymphocyte count greater than or equal to 800 cells/mm\^3~12. Platelets = 125,000 - 500,000/mm3~13. Hemoglobin within institutional normal range~14. Serum iron either within institutional normal range or accompanied by the site PI or designee approval~15. Serum ferritin within institutional normal range or accompanied by the site PI or designee approval~16. Alanine aminotransferase (ALT) less than or equal to 1.25 x institutional upper limit of normal (ULN)~17. Aspartate aminotransferase (AST) less than or equal to 1.25 x institutional ULN~18. Alkaline phosphatase (ALP) \<1.1 x institutional ULN~19. Total bilirubin within institutional normal range~20. Serum creatinine less than or equal to 1.1 x institutional ULN~21. Negative for HIV infection by an FDA-approved method of detection~    Criteria applicable to women of childbearing potential:~22. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment~23. Agreed to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study~EXCLUSION CRITERIA:~1. Breast-feeding or planning to become pregnant during the study.~   Participant has received any of the following substances:~2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment~3. Blood products within 16 weeks prior to enrollment~4. Live attenuated vaccines within 4 weeks prior to enrollment~5. Inactivated vaccines within 2 weeks prior to enrollment~6. Investigational research agents within 4 weeks prior to enrollment or planned to receive investigational products while on the study~7. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule~8. Current anti-TB (tuberculosis) prophylaxis or therapy~9. Previous investigational H1 influenza vaccine~10. Previous investigational ferritin-based vaccine~11. Receipt of a licensed influenza vaccine within 6 weeks before trial enrollment~    Participant has a history of any of the following clinically significant conditions:~12. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator~13. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema~14. Asthma that is not well controlled~15. Diabetes mellitus (type I or II), with the exception of gestational diabetes~16. Thyroid disease that is not well controlled~17. Idiopathic urticaria within the past year~18. Autoimmune disease or immunodeficiency~19. Hypertension that is not well controlled (baseline systolic \> 140 mmHg or diastolic \> 90 mmHg)~20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~21. Malignancy that is active or history of malignancy that is likely to recur during the period of the study.~22. Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years~23. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen~24. Guillain-Barré Syndrome~25. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a participant's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: H1ssF_3928 (20 mcg), ages 18-40 years (Type: EXPERIMENTAL): H1ssF_3928 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
- Group 2A: H1ssF_3928 (60 mcg), ages 18-40 years (Type: EXPERIMENTAL): H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
- Group 2B: H1ssF_3928 (60 mcg), ages 41-49 years (Type: EXPERIMENTAL): H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
- Group 2C: H1ssF_3928 (60 mcg), ages 50-59 years (Type: EXPERIMENTAL): H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
- Group 2D: H1ssF_3928 (60 mcg), ages 60-70 years (Type: EXPERIMENTAL): H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)

Based on this trial design, predict the completion outcome and termination type (if applicable).